Rigel Pharmaceuticals, Inc.
NASDAQRigel Pharmaceuticals heads into the summer with a notable contradiction at its core: short sellers are pushing back in, yet the Street just raised its most bullish price targets in months. Short interest has climbed back to its highest level in over six weeks. At 26.7% of the free float, it has recovered from a dip to 24.6% in mid-May and is now matching the late-April peak. The…
Snapshot as of 28 Jun 2026
Rigel Pharmaceuticals heads into the summer with a notable contradiction at its core: short sellers are pushing back in, yet the Street just raised its most bullish price targets in months. Short interest has climbed…
Rigel Pharmaceuticals heads into its May 14 earnings print with a freshly struck drug deal, a 12% pop on the session, and 21% of the float still held short. The catalyst was a licensing agreement with Arvinas and…
Rigel Pharmaceuticals heads into its May 14 earnings report as one of the more heavily shorted small-cap biotechs in the market — and yesterday's 12% price jump has done nothing to ease the tension. Short sellers are…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RIGL — free to start on ORTEX.
Sign up for free →Open RIGL on ORTEX